40769-81-1 Usage
Uses
Used in Pharmaceutical Industry:
1H-Pyrazolo[4,3-d]pyrimidine-5,7(4H,6H)-dione is used as a therapeutic agent for the treatment of hyperuricemia, a condition characterized by high levels of uric acid in the blood. It functions by inhibiting the enzyme xanthine oxidase, which is crucial in the production of uric acid, thereby reducing its levels and alleviating symptoms associated with gout and kidney stones.
Used in Treatment of Enzyme Disorders:
1H-Pyrazolo[4,3-d]pyrimidine-5,7(4H,6H)-dione is utilized as a treatment for certain enzyme disorders where the body's metabolic processes result in excessive uric acid production. By inhibiting xanthine oxidase, it helps manage the symptoms and complications arising from these conditions.
Used in Oncology:
In the field of oncology, 1H-Pyrazolo[4,3-d]pyrimidine-5,7(4H,6H)-dione is applied to address chemotherapy-induced hyperuricemia, a common side effect of cancer treatments that can lead to kidney damage if left untreated. Its ability to lower uric acid levels helps protect the kidneys and improve patient outcomes during chemotherapy.
Used in Research for Cardiovascular and Neurodegenerative Diseases:
1H-Pyrazolo[4,3-d]pyrimidine-5,7(4H,6H)-dione is also being investigated for its potential use in the treatment of cardiovascular diseases and neurodegenerative disorders. Its role in modulating uric acid levels and other biochemical pathways suggests it may have therapeutic benefits in these areas, although further research is required to establish its efficacy and safety in these applications.
Check Digit Verification of cas no
The CAS Registry Mumber 40769-81-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,0,7,6 and 9 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 40769-81:
(7*4)+(6*0)+(5*7)+(4*6)+(3*9)+(2*8)+(1*1)=131
131 % 10 = 1
So 40769-81-1 is a valid CAS Registry Number.
40769-81-1Relevant articles and documents
6-(Diazomethyl)-1,3-bis(methoxymethyl)uracil, synthesis and transformation into annulated pyrimidinediones
Zhang, Fuyi,Kulesza, Anna,Rani, Shikha,Bernet, Bruno,Vasella, Andrea
experimental part, p. 1201 - 1218 (2009/02/07)
6-(Diazomethyl)-1,3-bis(methoxymethyl)uracil (5) was prepared from the known aldehyde 3 by hydrazone formation and oxidation. Thermolysis of 5 and deprotection gave the pyrazolo[4,3-d]pyrimidine-5,7-diones 7a and 7b. Rh 2(OAc)4 catalyzed the transformation of 5 into to a 2 : 1 (Z)/(E) mixture of 1,2-diuracilylethenes 9 (67%). Heating (Z)-9 in 12n HCl at 95° led to electrocyclisation, oxidation, and deprotection to afford 73% of the pyrimido[5,4-f]quinazolinetetraone 12. The Rh2(OAc) 4-catalyzed reaction of 5 with 3,4-dihydro-2H-pyran and 2,3-dihydrofuran gave endo/exo-mixtures of the 2-oxabicyclo[4.1.0]heptane 13 (78%) and the 2-oxabicyclo[3.1.0]hexane 15 (86%), Their treatment with AlCl 3 or Me2AlCl promoted a vinylcyclopropane - cyclopentene rearrangement, leading to the pyrano- and furanocyclopenta[1,2-d] pyrimidinediones 14 (88%) and 16 (51%), respectively. Similarly, the addition product of 5 to 2-methoxypropene was transformed into the 5-methylcyclopenta- pyrimidinedione 18 (55%). The Rh2(OAc)4-catalyzed reaction of 5 with thiophene gave the exo-configured 2-thiabicyclo[3.1.0]hexane 19 (69%). The analoguous reaction with furan led to 8-oxabicyclo[3.2.1]oct-2-ene 20 (73%), and the reaction with (E)-2-styrylfuran yielded a diastereoisomeric mixture of hepta-1,4,6-trien-3-ones 21 (75%) that was transformed into the (1E,4E,6E)-configured hepta-1,4,6-trien-3-one 21 (60%) at ambient temperature.
